Phone: 1-800-226-2379

Study of ARQ 092 in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC)

Description

This is an open label, Phase 1/2 study of oral ARQ 092 (Miransertib) administered to subjects at least 2 years of age with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) (MOSAIC).

Eligibility Criteria

  • Ages Eligible for Study: 2 – 21 years old
  • Sexes Eligible for Study: All

Detailed inclusion and exclusion criteria as listed on clinicaltrials.gov

Contact

Principal Investigator:

Dr. Ionela Iacobas
Medical Director, Vascular Anomalies Center, Texas Children's Hospital
(832) 824-4819
ixiacoba@texaschildrens.org


Related Articles

ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum (October 2, 2019 - BioSpace)